Clinical Trials
91 trialsMK-5684-004
Merck Sharp & Dohme LLC
MK-2140-010
Merck Sharp & Dohme LLC
MK-2400-001
Merck Sharp & Dohme LLC
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
OLYMPIA-1
Regeneron Pharmaceuticals
EvoPAR-PR02
AstraZeneca
OLYMPIA-3
Regeneron Pharmaceuticals
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Aragon Pharmaceuticals, Inc.
AMPLITUDE
Janssen Research & Development, LLC
KLK2-PASenger
Janssen Research & Development, LLC
POLARIX
Hoffmann-La Roche
MAGNITUDE
Janssen Research & Development, LLC
EPCOREâ„¢FL-2
Genmab
OMAHA-003
Merck Sharp & Dohme LLC
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BioNTech SE
LEDA
Novartis
DEB
Chipscreen Biosciences, Ltd.
frontMIND
Incyte Corporation
ESCALADE
Acerta Pharma BV
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
GOLSEEK-1
Celgene
OLYMPIA-2
Regeneron Pharmaceuticals
CONTACT-02
Exelixis
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda
CRESCENDO
Acrotech Biopharma Inc.
ZUMA-22
Gilead Sciences
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Chipscreen Biosciences, Ltd.
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
177Lu-PSMA-I&T for Metastatic Castration-Resistant Prostate Cancer
Curium US LLC
KEYNOTE-921
Merck Sharp & Dohme LLC
CYCLONE 3
Eli Lilly and Company
CheckMate 7DX
Bristol-Myers Squibb
IPATential150
Hoffmann-La Roche
SELENE
Janssen Research & Development, LLC
KEYLYNK-010
Merck Sharp & Dohme LLC
ERA 223
Bayer
Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer
Janssen Research & Development, LLC
A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)
Janssen Research & Development, LLC
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Janssen Research & Development, LLC
EPCORE DLBCL-2
Genmab
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd.
CHRONOS-4
Bayer
Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Hoffmann-La Roche
Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL)
MEI Pharma, Inc.
KEYNOTE-921
Merck Sharp & Dohme LLC
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer
Tavanta Therapeutics
MADILYM
Mabion SA
Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
AB Science
ROBUST
Celgene